• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

An­oth­er lot of Mod­er­na's Rovi-made Spike­vax re­called af­ter par­tic­u­late found in vial

4 years ago
Pharma
Coronavirus

WP­P's VM­LY&R Health taps vet­er­an Gillis for CEO, amid re­fresh and first-ever health­care C-suite

4 years ago
Pharma
Marketing

Lon­za­'s au­toma­tive man­u­fac­tur­ing tech ac­quired by Mil­li­pore­Sig­ma

4 years ago
Pharma
Manufacturing

Rid­ing on coat­tails of Comir­naty suc­cess, BioN­Tech wins mR­NA man­u­fac­tur­ing con­tract with Ger­man gov­ern­ment

4 years ago
R&D
Manufacturing

AACR22: Ru­bius touts new da­ta for lead pro­gram, but shares rout­ed as in­vestors flee

4 years ago
R&D

What did we learn from Bio­gen's CMS slap­down? Da­ta rule

4 years ago
Bioregnum

Vi­a­tris dou­bles down on Sesame Work­shop col­lab­o­ra­tion, kick­ing in an­oth­er $1M

4 years ago
Pharma

As part of scheme to triple rev­enue this year, AGC adds on to Spain site for HPA­PIs

4 years ago
Pharma
Manufacturing

As­traZeneca ad­vances net-ze­ro car­bon goals, adding Hon­ey­well deal and out­sider over­sight among new ESG ef­forts

4 years ago
Pharma
Marketing

Flag­ship-backed mi­cro­bio­me com­pa­ny Kalei­do Bio­sciences shuts down

4 years ago
People
Startups

Phar­ma vets with Genen­tech con­nec­tion band to­geth­er to launch new im­munother­a­py start­up, though de­tails are scant

4 years ago
Financing
Startups

Fac­ing emp­ty re­serves by year's end, Lyra is rais­ing near­ly dou­ble its 2020 IPO as it en­ters PhI­II

4 years ago
Financing
Startups

BioCryst halts en­roll­ment in all stud­ies for its lead pipeline can­di­date — shares crash

4 years ago
R&D

De­layed at the EMA, a gene ther­a­py play­er is grap­pling with a cash crunch

4 years ago
Pharma
Cell/Gene Tx

Fed­er­al ju­ry con­victs Kansas chem pro­fes­sor on four counts in 'Chi­na Ini­tia­tive' case

4 years ago
China
Law

Har­poon's fall con­tin­ues as CMO de­parts weeks af­ter lead pro­gram axed

4 years ago
People
Startups

Af­ter tak­ing a $73M hit, J&J part­ner Gen­mab los­es ar­bi­tra­tion over roy­al­ties on megablock­buster Darza­lex

4 years ago
Deals
Pharma

Enam­ine will re­sume op­er­a­tions on lim­it­ed ba­sis, CEO says, as Russ­ian forces with­draw from Ukrain­ian cap­i­tal

4 years ago
Pharma

Xeno­trans­plant gene ed­i­tor eGe­n­e­sis snags trans­plant ex­pert as CMO; John Tsai, Su­sanne Schaf­fert among the hard cuts ...

4 years ago
Peer Review

CMS fi­nal­izes re­stric­tions on Bio­gen's Alzheimer's drug cov­er­age, will on­ly fund use in clin­i­cal tri­als

4 years ago
Pharma

When high costs mean un­filled pre­scrip­tions: New study digs in­to Medicare da­ta on se­niors skip­ping out

4 years ago
Pharma

House, Sen­ate Dems in­tro­duce leg­is­la­tion to com­bat 'abu­sive' phar­ma busi­ness prac­tices

4 years ago
Pharma

Al­ny­lam's Yvonne Green­street sees a mas­sive pay raise as John Maraganore pass­es the torch

4 years ago
People
Pharma

AI com­pa­nies join forces to boost da­ta use in man­u­fac­tur­ing; Con­struc­tion com­plete at 2 sites for added API ca­pac­i­ty

4 years ago
Manufacturing
First page Previous page 552553554555556557558 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times